Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. stocks have been trading up by 6.62 percent following upbeat coverage of its healthcare AI innovations.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TEM

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Piper Sandler lifted its view on Tempus AI to Overweight and hiked the price target to $76 from $56, leaning on the Personalis deal and strong INTerpath-001 MRD data.
The company is framed as a scaled precision-medicine diagnostics and data-licensing platform where multimodal clinical and molecular data are the core asset.
Q2 2026 for Tempus AI delivered 22% revenue growth to $382.5M, better gross profit, and a clean swing into positive net income and EBITDA.
A planned ~$1.5B Tempus AI acquisition of Personalis at $16.25 per share has triggered a seller-side fairness review.
That Personalis shareholder review is described as a routine process focused on deal fairness, not as a direct challenge to TEM.

Live Update At 12:32:24 EDT: On Tuesday, September 15, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 6.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TEM has been trading like a momentum name backed by real numbers. On the daily chart, Tempus AI has climbed from the high-$50s to mid-$60s over the last several sessions, closing near $66.33 after testing intraday highs above $66. The pattern is a series of higher lows after a brief dip from the low-$70s, showing buyers repeatedly stepping in on weakness.

Intraday, TEM’s 5‑minute tape shows a steady grind higher from around $63 at the open toward the mid‑$66s, with very little sharp downside. That kind of controlled trend often signals accumulation rather than a simple day-trader squeeze. For short-term traders, these tight intraday pullbacks around $0.50–$1.00 have been key spots to watch for bounces.

More Breaking News

Under the hood, Tempus AI’s Q2 2026 report backs the price action. Revenue came in at $382.5M, up 22% year over year, and the company flipped from losses to positive net income and EBITDA. With $815.99M in cash and short-term investments and a current ratio around 3.3, TEM looks funded to keep scaling. Margins are still in transition, but the 73.5% gross margin shows the core data and diagnostics business throws off attractive unit economics once operating costs get tamed.

Why Traders Are Watching TEM Right Now

Traders are watching Tempus AI because the story just lined up on three fronts: analyst sentiment, fundamentals, and a clear strategic swing. Piper Sandler’s upgrade of TEM to Overweight from Neutral, with a price target lifted to $76 from $56, is not a small tweak. It is a major re-rating. That target sits well above recent trading in the mid-$60s, so the Street is signaling more upside if the story stays on track.

The core driver behind that call is the pending Personalis acquisition. Tempus AI plans to pay $16.25 per share, valuing Personalis around $1.5B in enterprise value. The point of this deal is not just scale. It is about deepening a tumor-informed minimal residual disease (MRD) and tumor-sequencing platform, powered by data from the INTerpath-001 study that has already read out positively. For traders, this is exactly the kind of catalyst that can reprice an AI‑healthcare name when the Street buys into the synergy story.

At the same time, TEM is no longer just a “promise” name. Q2 2026 delivered strong oncology testing volume and fast growth in the Data and Applications segment, which is where the leveraged, high-margin AI upside lives. Tempus AI is being positioned as a precision‑medicine diagnostics and data‑licensing company, with multimodal clinical and molecular datasets at scale. That “context is the asset” framing matters, because it tells traders TEM is trying to build a durable data moat around AI‑driven drug discovery and development, not just sell one‑off tests.

The one point of noise is the shareholder investigation on the Personalis side. Right now it is described as a routine fairness check, not an attack on Tempus AI’s strategy. For active traders, that is more headline churn than thesis-breaking risk, but it can add volatility around deal milestones.

Conclusion

For active traders, TEM is now a textbook momentum‑meets‑fundamentals setup. The stock has reclaimed the mid‑$60s after a shakeout from the low‑$70s, while Wall Street is moving price targets higher and rewarding Tempus AI for profitable growth. Q2 2026 numbers — 22% revenue growth, positive net income, and EBITDA — tell us this is no longer a purely speculative AI medicine pitch. It is a scaling business with improving economics.

The Personalis deal is the big swing. At roughly $1.5B in value, it is not cheap, but it could lock in a stronger MRD and tumor-sequencing stack that fits perfectly with Tempus AI’s data‑driven model. Traders should expect the market to keep reacting to every update on integration, MRD data, and cross‑selling, because that is where the upside narrative now lives.

At the same time, TEM’s balance sheet — with hundreds of millions in cash and manageable leverage — gives the company room to execute without constant capital‑raising pressure, even with negative margins still visible on some long‑term ratios. For shorter‑term players, the key is to track how price behaves around prior resistance near the low‑$70s and recent support in the high‑$50s to low‑$60s. As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.” In the context of TEM, that means logging how the stock reacts to news on the Personalis integration, MRD readouts, and shifts in overall AI‑healthcare sentiment so that each trade around these catalysts becomes part of an ongoing trading playbook.

As Tim Sykes likes to say, “Patterns repeat because human nature doesn’t change — your job is to study them, react fast, and always, always cut losses quickly.” Tempus AI is giving traders a live case study in that mindset: a hot AI‑healthcare name with fresh catalysts, real numbers, and plenty of volatility for those prepared to manage risk. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!